메뉴 건너뛰기




Volumn 5, Issue 6, 2011, Pages 527-538

Amyloid imaging for Alzheimer's disease

Author keywords

Alzheimer's disease; Beta amyloid; Biomarker; Florbetapir; Pittsburgh compound B; Positron emission tomography

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; AV 45; AZD 2184; AZD 2995; AZD 4694; BAPINEUZUMAB; BIOLOGICAL MARKER; CARBON 11; FLORBETABEN; FLORBETAPIR F 18; FLUORODEOXYGLUCOSE F 18; FLUTEMETAMOL F 18; GANTENERUMAB; GE 067; GSK 933776; IMMUNOGLOBULIN; MABT5102A; PF 04494700; PITTSBURGH COMPOUND B; PONEZUMAB; SB 13; SEMAGACESTAT; SOLANEZUMAB; TRACER; UNCLASSIFIED DRUG; VANUTIDE CRIDIFICAR;

EID: 80054888536     PISSN: 17530059     EISSN: 17530067     Source Type: Journal    
DOI: 10.1517/17530059.2011.617365     Document Type: Review
Times cited : (1)

References (106)
  • 2
    • 80054964173 scopus 로고    scopus 로고
    • Clinical diagnosis of Alzheimers disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimers Disease
    • McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimers disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimers Disease. Neurology 2011;77(4):333
    • (2011) Neurology , vol.77 , Issue.4 , pp. 333
    • McKhann, G.1    Drachman, D.2    Folstein, M.3
  • 3
    • 79956076567 scopus 로고    scopus 로고
    • Introduction to the recommendations from the National Institute on Aging-Alzheimers Association workgroups on diagnostic guidelines for Alzheimers disease
    • Jack CR Jr, Albert MS, Knopman DS, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimers Association workgroups on diagnostic guidelines for Alzheimers disease. Alzheimers Dement J Alzheimers Association 2011;7(3):257-62
    • (2011) Alzheimers Dement J Alzheimers Association , vol.7 , Issue.3 , pp. 257-62
    • Jack, Jr.C.R.1    Albert, M.S.2    Knopman, D.S.3
  • 5
    • 48749109915 scopus 로고    scopus 로고
    • The ART of loss: Abeta imaging in the evaluation of Alzheimers disease and other dementias
    • Villemagne V, Fodero-Tavoletti M, Pike K, et al. The ART of loss: Abeta imaging in the evaluation of Alzheimers disease and other dementias. Mol Neurobiol 2008;38(1):1-15
    • (2008) Mol Neurobiol , vol.38 , Issue.1 , pp. 1-15
    • Villemagne, V.1    Fodero-Tavoletti, M.2    Pike, K.3
  • 6
    • 70350266228 scopus 로고    scopus 로고
    • Amyloid imaging in aging and dementia: Testing the amyloid hypothesis in vivo
    • Rabinovici GD, Jagust WJ. Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo. Behav Neurol 2009;21(1):117-28
    • (2009) Behav Neurol , vol.21 , Issue.1 , pp. 117-28
    • Rabinovici, G.D.1    Jagust, W.J.2
  • 7
    • 68449090629 scopus 로고    scopus 로고
    • Update on amyloid imaging: From healthy aging to Alzheimers disease
    • Wolk D, Klunk W. Update on amyloid imaging: from healthy aging to Alzheimers disease. Curr Neurol Neurosci Rep 2009;9(5):345-52
    • (2009) Curr Neurol Neurosci Rep , vol.9 , Issue.5 , pp. 345-52
    • Wolk, D.1    Klunk, W.2
  • 8
    • 0035902875 scopus 로고    scopus 로고
    • Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain
    • DOI 10.1016/S0024-3205(01)01232-2, PII S0024320501012322
    • Klunk WE, Wang Y, Huang G-F, et al. Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. Life Sci 2001;69(13):1471-84 (Pubitemid 32786721)
    • (2001) Life Sciences , vol.69 , Issue.13 , pp. 1471-1484
    • Klunk, W.E.1    Wang, Y.2    Huang, G.-F.3    Debnath, M.L.4    Holt, D.P.5    Mathis, C.A.6
  • 10
    • 56749112290 scopus 로고    scopus 로고
    • The future of amyloid-beta imaging: A tale of radionuclides and tracer proliferation
    • Klunk WE, Mathis CA. The future of amyloid-beta imaging: a tale of radionuclides and tracer proliferation. Curr Opin Neurol 2008;21(6):683-7
    • (2008) Curr Opin Neurol , vol.21 , Issue.6 , pp. 683-7
    • Klunk, W.E.1    Mathis, C.A.2
  • 11
    • 79958033200 scopus 로고    scopus 로고
    • The importance of appropriate partial volume correction for PET quantification in Alzheimers disease
    • Thomas BA, Erlandsson K, Modat M, et al. The importance of appropriate partial volume correction for PET quantification in Alzheimers disease. Eur J Nucl Med Mol Imaging 2011;38(6):1104-19
    • (2011) Eur J Nucl Med Mol Imaging , vol.38 , Issue.6 , pp. 1104-19
    • Thomas, B.A.1    Erlandsson, K.2    Modat, M.3
  • 12
    • 77956384880 scopus 로고    scopus 로고
    • 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial
    • Vandenberghe R, Van Laere K, Ivanoiu A, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol 2010;68(3):319-29
    • (2010) Ann Neurol , vol.68 , Issue.3 , pp. 319-29
    • Vandenberghe, R.1    Van Laere, K.2    Ivanoiu, A.3
  • 13
    • 68249141258 scopus 로고    scopus 로고
    • Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease
    • Nelissen N, Van Laere K, Thurfjell L, et al. Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med 2009;50(8):1251-9
    • (2009) J Nucl Med , vol.50 , Issue.8 , pp. 1251-9
    • Nelissen, N.1    Van Laere, K.2    Thurfjell, L.3
  • 14
    • 66149104129 scopus 로고    scopus 로고
    • Whole-body biodistribution and radiation dosimetry of 18F-GE067: A radioligand for in vivo brain amyloid imaging
    • Koole M, Lewis DM, Buckley C, et al. Whole-body biodistribution and radiation dosimetry of 18F-GE067: a radioligand for in vivo brain amyloid imaging. J Nucl Med 2009;50(5):818-22
    • (2009) J Nucl Med , vol.50 , Issue.5 , pp. 818-22
    • Koole, M.1    Lewis, D.M.2    Buckley, C.3
  • 15
    • 77952552594 scopus 로고    scopus 로고
    • Whole-body biodistribution and brain PET imaging with [18F]AV-45 a novel amyloid imaging agent - A pilot study
    • Lin K-J, Hsu W-C, Hsiao I-T, et al. Whole-body biodistribution and brain PET imaging with [18F]AV-45, a novel amyloid imaging agent - a pilot study. Nucl Med Biol 2010;37(4):497-508
    • (2010) Nucl Med Biol , vol.37 , Issue.4 , pp. 497-508
    • Lin, K.-J.1    Hsu, W.-C.2    Hsiao, I.-T.3
  • 16
    • 77953937194 scopus 로고    scopus 로고
    • In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (flobetapir F 18)
    • Wong DF, Rosenberg PB, Zhou Y, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (flobetapir F 18). J Nucl Med 2010;51(6):913-20
    • (2010) J Nucl Med , vol.51 , Issue.6 , pp. 913-20
    • Wong, D.F.1    Rosenberg, P.B.2    Zhou, Y.3
  • 17
    • 70350716476 scopus 로고    scopus 로고
    • Preclinical properties of 18F-AV-45: A PET agent for Abeta plaques in the brain
    • Choi SR, Golding G, Zhuang Z, et al. Preclinical properties of 18F-AV-45: A PET agent for Abeta plaques in the brain. J Nucl Med 2009;50(11):1887-94
    • (2009) J Nucl Med , vol.50 , Issue.11 , pp. 1887-94
    • Choi, S.R.1    Golding, G.2    Zhuang, Z.3
  • 18
    • 38149081191 scopus 로고    scopus 로고
    • Imaging of amyloid-beta in Alzheimers disease with 18F-BAY94-9172, a novel PET tracer: Proof of mechanism
    • Rowe CC, Ackerman U, Browne W, et al. Imaging of amyloid-beta in Alzheimers disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 2008;7(2):129-35
    • (2008) Lancet Neurol , vol.7 , Issue.2 , pp. 129-35
    • Rowe, C.C.1    Ackerman, U.2    Browne, W.3
  • 19
    • 80051688987 scopus 로고    scopus 로고
    • Amyloid imaging with 18F-florbetaben in Alzheimer disease and other dementias
    • Villemagne VL, Ong K, Mulligan RS, et al. Amyloid imaging with 18F-florbetaben in Alzheimer disease and other dementias. J Nucl Med 2011;52(8):1210-17
    • (2011) J Nucl Med , vol.52 , Issue.8 , pp. 1210-17
    • Villemagne, V.L.1    Ong, K.2    Mulligan, R.S.3
  • 20
    • 77954338544 scopus 로고    scopus 로고
    • Characterization of AZD4694, a novel fluorinated Abeta plaque neuroimaging PET radioligand
    • Jureus A, Swahn B-M, Sandell J, et al. Characterization of AZD4694, a novel fluorinated Abeta plaque neuroimaging PET radioligand. J Neurochem 2010;114(3):784-94
    • (2010) J Neurochem , vol.114 , Issue.3 , pp. 784-94
    • Jureus, A.1    Swahn, B.-M.2    Sandell, J.3
  • 25
    • 0035893245 scopus 로고    scopus 로고
    • Binding characteristics of radiofluorinated 6-dialkylamino-2- naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimers disease
    • Agdeppa ED, Kepe V, Liu J, et al. Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimers disease. J Neurosci 2001;21(24):RC189-RC89
    • (2001) J Neurosci , vol.21 , Issue.24
    • Agdeppa, E.D.1    Kepe, V.2    Liu, J.3
  • 26
    • 0041335200 scopus 로고    scopus 로고
    • Molecular-imaging probe 2-(1-{6-[(2-fluoroethyl)(methyl) amino]-2-naphthyl}ethylidene) malononitrile labels prion plaques in vitro
    • Bresjanac M, Smid LM, Vovko TD, et al. Molecular-imaging probe 2-(1-{6- [(2-fluoroethyl)(methyl) amino]-2- naphthyl}ethylidene) malononitrile labels prion plaques in vitro. J Neurosci 2003;23(22):8029-33 (Pubitemid 37082455)
    • (2003) Journal of Neuroscience , vol.23 , Issue.22 , pp. 8029-8033
    • Bresjanac, M.1    Smid, L.M.2    Vovko, T.D.3    Petric, A.4    Barrio, J.R.5    Popovic, M.6
  • 27
    • 33745028473 scopus 로고    scopus 로고
    • The 2,6-disubstituted naphthalene derivative FDDNP labeling reliably predicts Congo red birefringence of protein deposits in brain sections of selected human neurodegenerative diseases
    • DOI 10.1111/j.1750-3639.2006.00006.x
    • Smid LM, Vovko TD, Popovic M, et al. The 2,6-disubstituted naphthalene derivative FDDNP labeling reliably predicts Congo red birefringence of protein deposits in brain sections of selected human neurodegenerative diseases. Brain Pathol 2006;16(2):124-30 (Pubitemid 43876472)
    • (2006) Brain Pathology , vol.16 , Issue.2 , pp. 124-130
    • Smid, L.M.1    Vovko, T.D.2    Popovic, M.3    Petric, A.4    Kepe, V.5    Barrio, J.R.6    Vidmar, G.7    Bresjanac, M.8
  • 28
    • 53049093702 scopus 로고    scopus 로고
    • Multitracer PET imaging of amyloid plaques and neurofibrillary tangles in Alzheimers disease
    • Shin J, Lee S-Y, Kim S-H, et al. Multitracer PET imaging of amyloid plaques and neurofibrillary tangles in Alzheimers disease. Neuroimage 2008;43(2):236-44
    • (2008) Neuroimage , vol.43 , Issue.2 , pp. 236-44
    • Shin, J.1    Lee, S.-Y.2    Kim, S.-H.3
  • 29
    • 77955707891 scopus 로고    scopus 로고
    • Voxel-based analysis of Alzheimers disease PET imaging using a triplet of radiotracers: PIB FDDNP and FDG
    • Shin J, Lee S-Y, Kim SJ, et al. Voxel-based analysis of Alzheimers disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG. Neuroimage 2010;52(2):488-96
    • (2010) Neuroimage , vol.52 , Issue.2 , pp. 488-96
    • Shin, J.1    Lee, S.-Y.2    Kim, S.J.3
  • 30
    • 34248579112 scopus 로고    scopus 로고
    • 2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl)-6-(2-[fluoro]ethoxy) benzoxazole: A novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients
    • DOI 10.2967/jnumed.106.037556
    • Kudo Y, Okamura N, Furumoto S, et al. 2-(2-[2-dimethylaminothiazol-5-yl] ethenyl)-6- (2-[fluoro]ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimers disease patients. J Nucl Med 2007;48(4):553-61 (Pubitemid 47571409)
    • (2007) Journal of Nuclear Medicine , vol.48 , Issue.4 , pp. 553-561
    • Kudo, Y.1    Okamura, N.2    Furumoto, S.3    Tashiro, M.4    Furukawa, K.5    Maruyama, M.6    Itoh, M.7    Iwata, R.8    Yanai, K.9    Arai, H.10
  • 31
    • 77952090854 scopus 로고    scopus 로고
    • In vivo detection of prion amyloid plaques using [11C]BF-227 PET
    • Okamura N, Shiga Y, Furumoto S, et al. In vivo detection of prion amyloid plaques using [11C]BF-227 PET. Eur J Nucl Med Mol Imaging 2010;37(5):934-41
    • (2010) Eur J Nucl Med Mol Imaging , vol.37 , Issue.5 , pp. 934-41
    • Okamura, N.1    Shiga, Y.2    Furumoto, S.3
  • 32
    • 77952982672 scopus 로고    scopus 로고
    • In vivo visualization of alpha-synuclein deposition by carbon-11-labelled 2-[2-(2- dimethylaminothiazol-5-yl)ethenyl]-6-[2- (fluoro)ethoxy]benzoxazole positron emission tomography in multiple system atrophy
    • Kikuchi A, Takeda A, Okamura N, et al. In vivo visualization of alpha-synuclein deposition by carbon-11-labelled 2-[2-(2- dimethylaminothiazol- 5-yl)ethenyl]-6-[2- (fluoro)ethoxy]benzoxazole positron emission tomography in multiple system atrophy. Brain 2010;133(6):1772-8
    • (2010) Brain , vol.133 , Issue.6 , pp. 1772-8
    • Kikuchi, A.1    Takeda, A.2    Okamura, N.3
  • 33
    • 77952369391 scopus 로고    scopus 로고
    • Amyloid PET in mild cognitive impairment and Alzheimers disease with BF-227: Comparison to FDG-PET
    • Furukawa K, Okamura N, Tashiro M, et al. Amyloid PET in mild cognitive impairment and Alzheimers disease with BF-227: comparison to FDG-PET. J Neurol 2010;257(5):721-7
    • (2010) J Neurol , vol.257 , Issue.5 , pp. 721-7
    • Furukawa, K.1    Okamura, N.2    Tashiro, M.3
  • 34
    • 68549085069 scopus 로고    scopus 로고
    • In vitro characterisation of BF227 binding to [alpha]-synuclein/Lewy bodies
    • Fodero-Tavoletti MT, Mulligan RS, Okamura N, et al. In vitro characterisation of BF227 binding to [alpha]-synuclein/Lewy bodies. Eur J Pharmacol 2009;617(1-3):54-8
    • (2009) Eur J Pharmacol , vol.617 , Issue.1-3 , pp. 54-8
    • Fodero-Tavoletti, M.T.1    Mulligan, R.S.2    Okamura, N.3
  • 35
    • 69549089908 scopus 로고    scopus 로고
    • Comparison study of amyloid PET and voxel-based morphometry analysis in mild cognitive impairment and Alzheimers disease
    • Waragai M, Okamura N, Furukawa K, et al. Comparison study of amyloid PET and voxel-based morphometry analysis in mild cognitive impairment and Alzheimers disease. J Neurol Sci 2009;285(1-2):100-8
    • (2009) J Neurol Sci , vol.285 , Issue.1-2 , pp. 100-8
    • Waragai, M.1    Okamura, N.2    Furukawa, K.3
  • 37
    • 79951520786 scopus 로고    scopus 로고
    • In vivo fibrillar beta-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults
    • Sojkova J, Driscoll I, Iacono D, et al. In vivo fibrillar beta-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults. Arch Neurol 2011;68(2):232-40
    • (2011) Arch Neurol , vol.68 , Issue.2 , pp. 232-40
    • Sojkova, J.1    Driscoll, I.2    Iacono, D.3
  • 38
    • 78751546481 scopus 로고    scopus 로고
    • Use of florbetapir-PET for imaging beta-amyloid pathology
    • Clark CM, Schneider JA, Bedell BJ, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 2011;305(3):275-83
    • (2011) JAMA , vol.305 , Issue.3 , pp. 275-83
    • Clark, C.M.1    Schneider, J.A.2    Bedell, B.J.3
  • 39
    • 78751532097 scopus 로고    scopus 로고
    • Mapping out biomarkers for Alzheimer disease
    • Breteler MMB. Mapping out biomarkers for Alzheimer disease. JAMA 2011;305(3):304-5
    • (2011) JAMA , vol.305 , Issue.3 , pp. 304-5
    • Mmb, B.1
  • 42
    • 74049124939 scopus 로고    scopus 로고
    • In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia
    • Burack MA, Hartlein J, Flores HP, et al. In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. Neurology 2010;74(1):77-84
    • (2010) Neurology , vol.74 , Issue.1 , pp. 77-84
    • Burack, M.A.1    Hartlein, J.2    Flores, H.P.3
  • 43
    • 79960996008 scopus 로고    scopus 로고
    • Ante mortem amyloid imaging and beta-amyloid pathology in a case with dementia with Lewy bodies
    • In press
    • Kantarci K, Yang C, Schneider JA, et al. Ante mortem amyloid imaging and beta-amyloid pathology in a case with dementia with Lewy bodies. Neurobiol Aging 2010; In press
    • (2010) Neurobiol Aging
    • Kantarci, K.1    Yang, C.2    Schneider, J.A.3
  • 46
    • 77955474542 scopus 로고    scopus 로고
    • The Alzheimers disease neuroimaging initiative positron emission tomography core
    • Jagust WJ, Bandy D, Chen K, et al. The Alzheimers disease neuroimaging initiative positron emission tomography core. Alzheimers Dement 2010;6(3):221-9
    • (2010) Alzheimers Dement , vol.6 , Issue.3 , pp. 221-9
    • Jagust, W.J.1    Bandy, D.2    Chen, K.3
  • 47
    • 55949117032 scopus 로고    scopus 로고
    • Frequent amyloid deposition without significant cognitive impairment among the elderly
    • Aizenstein HJ, Nebes RD, Saxton JA, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 2008;65(11):1509-17
    • (2008) Arch Neurol , vol.65 , Issue.11 , pp. 1509-17
    • Aizenstein, H.J.1    Nebes, R.D.2    Saxton, J.A.3
  • 50
    • 66549127860 scopus 로고    scopus 로고
    • Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects
    • Mormino EC, Kluth JT, Madison CM, et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 2009;132(Pt 5):1310-23
    • (2009) Brain , vol.132 , Issue.PART 5 , pp. 1310-23
    • Mormino, E.C.1    Kluth, J.T.2    Madison, C.M.3
  • 52
    • 66149084048 scopus 로고    scopus 로고
    • Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimers disease
    • Reiman EM, Chen K, Liu X, et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimers disease. Proc Natl Acad Sci USA 2009;106(16):6820-5
    • (2009) Proc Natl Acad Sci USA , vol.106 , Issue.16 , pp. 6820-5
    • Reiman, E.M.1    Chen, K.2    Liu, X.3
  • 53
    • 79551495391 scopus 로고    scopus 로고
    • Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease
    • Villemagne VL, Pike KE, Chetelat G, et al. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann Neurol 2011;69(1):181-92
    • (2011) Ann Neurol , vol.69 , Issue.1 , pp. 181-92
    • Villemagne, V.L.1    Pike, K.E.2    Chetelat, G.3
  • 54
    • 77954033257 scopus 로고    scopus 로고
    • Amyloid imaging results from the Australian Imaging Biomarkers and Lifestyle (AIBL) study of aging
    • Rowe CC, Ellis KA, Rimajova M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010;31(8):1275-83
    • (2010) Neurobiol Aging , vol.31 , Issue.8 , pp. 1275-83
    • Rowe, C.C.1    Ellis, K.A.2    Rimajova, M.3
  • 55
    • 72049130805 scopus 로고    scopus 로고
    • Hypothetical model of dynamic biomarkers of the Alzheimers pathological cascade
    • Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimers pathological cascade. Lancet Neurol 2010;9(1):119-28
    • (2010) Lancet Neurol , vol.9 , Issue.1 , pp. 119-28
    • Jack, Jr.C.R.1    Knopman, D.S.2    Jagust, W.J.3
  • 57
    • 78650415960 scopus 로고    scopus 로고
    • Positron emission tomography with Pittsburgh compound B in diagnosis of early stage Alzheimers disease
    • Jia J, Sun B, Guo Z, et al. Positron emission tomography with Pittsburgh compound B in diagnosis of early stage Alzheimers disease. Cell Biochem Biophys 2011;59(1):57-62
    • (2011) Cell Biochem Biophys , vol.59 , Issue.1 , pp. 57-62
    • Jia, J.1    Sun, B.2    Guo, Z.3
  • 58
    • 77957257228 scopus 로고    scopus 로고
    • Clinically different stages of Alzheimers disease associated by amyloid deposition with [11C]-PIB PET imaging
    • Hatashita S, Yamasaki H. Clinically different stages of Alzheimers disease associated by amyloid deposition with [11C]-PIB PET imaging. J Alzheimers Dis 2010;21(3):995-1003
    • (2010) J Alzheimers Dis , vol.21 , Issue.3 , pp. 995-1003
    • Hatashita, S.1    Yamasaki, H.2
  • 59
    • 77955528206 scopus 로고    scopus 로고
    • Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18 F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls
    • Devanand DP, Mikhno A, Pelton GH, et al. Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18 F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls. J Geriatr Psychiatry Neurol 2010;23(3):185-98
    • (2010) J Geriatr Psychiatry Neurol , vol.23 , Issue.3 , pp. 185-98
    • Devanand, D.P.1    Mikhno, A.2    Pelton, G.H.3
  • 60
    • 49349092320 scopus 로고    scopus 로고
    • PET imaging of amyloid deposition in patients with mild cognitive impairment
    • Forsberg A, Engler H, Almkvist O, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008;29(10):1456-65
    • (2008) Neurobiol Aging , vol.29 , Issue.10 , pp. 1456-65
    • Forsberg, A.1    Engler, H.2    Almkvist, O.3
  • 61
    • 66549106850 scopus 로고    scopus 로고
    • Serial PIB and MRI in normal, mild cognitive impairment and Alzheimers disease: Implications for sequence of pathological events in Alzheimers disease
    • Jack CR, Lowe VJ, Weigand SD, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimers disease: implications for sequence of pathological events in Alzheimers disease. Brain 2009;132(5):1355-65
    • (2009) Brain , vol.132 , Issue.5 , pp. 1355-65
    • Jack, C.R.1    Lowe, V.J.2    Weigand, S.D.3
  • 63
    • 85058205144 scopus 로고    scopus 로고
    • Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimers disease
    • In press
    • Kadir A, Almkvist O, Forsberg A, et al. Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimers disease. Neurobiol Aging; In press
    • Neurobiol Aging
    • Kadir, A.1    Almkvist, O.2    Forsberg, A.3
  • 64
    • 70350164263 scopus 로고    scopus 로고
    • Follow-up of [11C]. PIB uptake and brain volume in patients with Alzheimer disease and controls
    • Scheinin NM, Aalto S, Koikkalainen J, et al. Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls. Neurology 2009;73(15):1186-92
    • (2009) Neurology , vol.73 , Issue.15 , pp. 1186-92
    • Scheinin, N.M.1    Aalto, S.2    Koikkalainen, J.3
  • 65
    • 77949300796 scopus 로고    scopus 로고
    • (11)C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimers disease treated with bapineuzumab: A phase 2 double-blind placebo-controlled ascending-dose study
    • Rinne JO, Brooks DJ, Rossor MN, et al. (11)C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimers disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010;9(4):363-72
    • (2010) Lancet Neurol , vol.9 , Issue.4 , pp. 363-72
    • Rinne, J.O.1    Brooks, D.J.2    Rossor, M.N.3
  • 66
    • 78049427912 scopus 로고    scopus 로고
    • Progression of cerebral amyloid load is associated with the apolipoprotein e epsilon4 genotype in Alzheimers disease
    • Grimmer T, Tholen S, Yousefi BH, et al. Progression of cerebral amyloid load is associated with the apolipoprotein E epsilon4 genotype in Alzheimers disease. Biol Psychiatry 2010;68(10):879-84
    • (2010) Biol Psychiatry , vol.68 , Issue.10 , pp. 879-84
    • Grimmer, T.1    Tholen, S.2    Yousefi, B.H.3
  • 67
    • 79953177902 scopus 로고    scopus 로고
    • Amyloid PET imaging in patients with mild cognitive impairment
    • Koivunen J, Scheinin N, Virta JR, et al. Amyloid PET imaging in patients with mild cognitive impairment. Neurology 2011;76:1085-90
    • (2011) Neurology , vol.76 , pp. 1085-90
    • Koivunen, J.1    Scheinin, N.2    Virta, J.R.3
  • 68
    • 73549106106 scopus 로고    scopus 로고
    • Cognitive decline and brain volume loss as signatures of cerebral Amyloid-beta peptide deposition identified with Pittsburgh compound B: Cognitive decline associated with Abeta deposition
    • Storandt M, Mintun MA, Head D, Morris JC. Cognitive decline and brain volume loss as signatures of cerebral Amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. Arch Neurol 2009;66(12):1476-81
    • (2009) Arch Neurol , vol.66 , Issue.12 , pp. 1476-81
    • Storandt, M.1    Mintun, M.A.2    Head, D.3    Morris, J.C.4
  • 69
    • 77949701876 scopus 로고    scopus 로고
    • High PIB retention in Alzheimers disease is an early event with complex relationship with CSF biomarkers and functional parameters
    • Forsberg A, Almkvist O, Engler H, et al. High PIB retention in Alzheimers disease is an early event with complex relationship with CSF biomarkers and functional parameters. Curr Alzheimer Res 2010;7(1):56-66
    • (2010) Curr Alzheimer Res , vol.7 , Issue.1 , pp. 56-66
    • Forsberg, A.1    Almkvist, O.2    Engler, H.3
  • 70
    • 77954033982 scopus 로고    scopus 로고
    • 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects
    • Apostolova LG, Hwang KS, Andrawis JP, et al. 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. Neurobiol Aging 2010;31(8):1284-303
    • (2010) Neurobiol Aging , vol.31 , Issue.8 , pp. 1284-303
    • Apostolova, L.G.1    Hwang, K.S.2    Andrawis, J.P.3
  • 71
    • 80053638033 scopus 로고    scopus 로고
    • Lack of association between 11C-PiB and longitudinal brain atrophy in non-demented older individuals
    • In press
    • Driscoll I, Zhou Y, An Y, et al. Lack of association between 11C-PiB and longitudinal brain atrophy in non-demented older individuals. Neurobiol Aging; In press
    • Neurobiol Aging
    • Driscoll, I.1    Zhou, Y.2    An, Y.3
  • 72
    • 77950535797 scopus 로고    scopus 로고
    • Relationship between atrophy and beta-amyloid deposition in Alzheimer disease
    • Chetelat G, Villemagne VL, Bourgeat P, et al. Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann Neurol 2010;67(3):317-24
    • (2010) Ann Neurol , vol.67 , Issue.3 , pp. 317-24
    • Chetelat, G.1    Villemagne, V.L.2    Bourgeat, P.3
  • 73
    • 33749150163 scopus 로고    scopus 로고
    • Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry
    • DOI 10.1007/s00401-006-0127-z
    • Braak H, Alafuzoff I, Arzberger T, et al. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol (Berl) 2006;112(4):389-404 (Pubitemid 44469160)
    • (2006) Acta Neuropathologica , vol.112 , Issue.4 , pp. 389-404
    • Braak, H.1    Alafuzoff, I.2    Arzberger, T.3    Kretzschmar, H.4    Tredici, K.5
  • 74
    • 70349582720 scopus 로고    scopus 로고
    • Conversion of amyloid positive and negative MCI to AD over 3 years
    • Okello A, Koivunen J, Edison P, et al. Conversion of amyloid positive and negative MCI to AD over 3 years. Neurology 2009;73(10):754-60
    • (2009) Neurology , vol.73 , Issue.10 , pp. 754-60
    • Okello, A.1    Koivunen, J.2    Edison, P.3
  • 75
    • 53849132759 scopus 로고    scopus 로고
    • PET amyloid ligand [11C]. PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment
    • Koivunen J, Pirttila T, Kemppainen N, et al. PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment. Dement Geriatr Cogn Disord 2008;26(4):378-83
    • (2008) Dement Geriatr Cogn Disord , vol.26 , Issue.4 , pp. 378-83
    • Koivunen, J.1    Pirttila, T.2    Kemppainen, N.3
  • 76
    • 73549092137 scopus 로고    scopus 로고
    • Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease
    • Morris JC, Roe CM, Grant EA, et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol 2009;66(12):1469-75
    • (2009) Arch Neurol , vol.66 , Issue.12 , pp. 1469-75
    • Morris, J.C.1    Roe, C.M.2    Grant, E.A.3
  • 77
    • 67249121764 scopus 로고    scopus 로고
    • Amyloid imaging in mild cognitive impairment subtypes
    • Wolk DA, Price JC, Saxton JA, et al. Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol 2009;65(5):557-68
    • (2009) Ann Neurol , vol.65 , Issue.5 , pp. 557-68
    • Wolk, D.A.1    Price, J.C.2    Saxton, J.A.3
  • 78
    • 4544335597 scopus 로고    scopus 로고
    • Mild cognitive impairment as a diagnostic entity
    • DOI 10.1111/j.1365-2796.2004.01388.x
    • Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004;256(3):183-94. Available from: www.adni-info.org (Pubitemid 39222988)
    • (2004) Journal of Internal Medicine , vol.256 , Issue.3 , pp. 183-194
    • Petersen, R.C.1
  • 80
    • 77953340628 scopus 로고    scopus 로고
    • In vivo amyloid deposition and neuropathological findings after humanized amyloid beta-specific monoclonal antibodies therapy in a patient with Alzheimers disease
    • Lopez OL, Hamilton R, Ikonomovic M, et al. In vivo amyloid deposition and neuropathological findings after humanized amyloid beta-specific monoclonal antibodies therapy in a patient with Alzheimers disease. Alzheimers Dement 2009;5(4):P64-5
    • (2009) Alzheimers Dement , vol.5 , Issue.4
    • Lopez, O.L.1    Hamilton, R.2    Ikonomovic, M.3
  • 81
    • 77955704022 scopus 로고    scopus 로고
    • Integrating ADNI results into Alzheimers disease drug development programs
    • Cummings JL. Integrating ADNI results into Alzheimers disease drug development programs. Neurobiol Aging 2010;31(8):1481-92
    • (2010) Neurobiol Aging , vol.31 , Issue.8 , pp. 1481-92
    • Cummings, J.L.1
  • 82
    • 77954028812 scopus 로고    scopus 로고
    • Enrichment through biomarkers in clinical trials of Alzheimers drugs in patients with mild cognitive impairment
    • e1
    • Lorenzi M, Donohue M, Paternico D, et al. Enrichment through biomarkers in clinical trials of Alzheimers drugs in patients with mild cognitive impairment. Neurobiol Aging 2010;31(8):1443-51; e1
    • (2010) Neurobiol Aging , vol.31 , Issue.8 , pp. 1443-51
    • Lorenzi, M.1    Donohue, M.2    Paternico, D.3
  • 86
    • 52449089987 scopus 로고    scopus 로고
    • Thirty years of Alzheimers disease genetics: The implications of systematic meta-analyses
    • Bertram L, Tanzi RE. Thirty years of Alzheimers disease genetics: the implications of systematic meta-analyses. Nat Rev Neurosci 2008;9(10):768-78
    • (2008) Nat Rev Neurosci , vol.9 , Issue.10 , pp. 768-78
    • Bertram, L.1    Tanzi, R.E.2
  • 87
    • 68249134074 scopus 로고    scopus 로고
    • The role of apolipoprotein e in Alzheimers disease
    • Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimers disease. Neuron 2009;63(3):287-303
    • (2009) Neuron , vol.63 , Issue.3 , pp. 287-303
    • Kim, J.1    Basak, J.M.2    Holtzman, D.M.3
  • 88
    • 77649314191 scopus 로고    scopus 로고
    • APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging
    • Morris JC, Roe CM, Xiong C, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 2010;67(1):122-31
    • (2010) Ann Neurol , vol.67 , Issue.1 , pp. 122-31
    • Morris, J.C.1    Roe, C.M.2    Xiong, C.3
  • 89
    • 67549147148 scopus 로고    scopus 로고
    • Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease
    • Drzezga A, Grimmer T, Henriksen G, et al. Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology 2009;72(17):1487-94
    • (2009) Neurology , vol.72 , Issue.17 , pp. 1487-94
    • Drzezga, A.1    Grimmer, T.2    Henriksen, G.3
  • 91
    • 77949555201 scopus 로고    scopus 로고
    • Pittsburgh compound-B and Alzheimers disease biomarkers in CSF plasma and urine: An exploratory study
    • Degerman Gunnarsson M, Lindau M, Wall A, et al. Pittsburgh compound-B and Alzheimers disease biomarkers in CSF, plasma and urine: an exploratory study. Dement Geriatr Cogn Disord 2010;29(3):204-12
    • (2010) Dement Geriatr Cogn Disord , vol.29 , Issue.3 , pp. 204-12
    • Degerman Gunnarsson, M.1    Lindau, M.2    Wall, A.3
  • 92
    • 77149159754 scopus 로고    scopus 로고
    • Cortical binding of Pittsburgh compound B an endophenotype for genetic studies of Alzheimers disease
    • Hinrichs AL, Mintun MA, Head D, et al. Cortical binding of Pittsburgh compound B, an endophenotype for genetic studies of Alzheimers disease. Biol Psychiatry 2010;67(6):581-3
    • (2010) Biol Psychiatry , vol.67 , Issue.6 , pp. 581-3
    • Hinrichs, A.L.1    Mintun, M.A.2    Head, D.3
  • 93
    • 77950546575 scopus 로고    scopus 로고
    • Increased fibrillar amyloid-beta burden in normal individuals with a family history of late-onset Alzheimers
    • Mosconi L, Rinne JO, Tsui WH, et al. Increased fibrillar amyloid-beta burden in normal individuals with a family history of late-onset Alzheimers. Proc Natl Acad Sci USA 2010;107(13):5949-54
    • (2010) Proc Natl Acad Sci USA , vol.107 , Issue.13 , pp. 5949-54
    • Mosconi, L.1    Rinne, J.O.2    Tsui, W.H.3
  • 94
    • 65249159879 scopus 로고    scopus 로고
    • Cerebrospinal fluid biomarker signature in Alzheimers disease neuroimaging initiative subjects
    • Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimers disease neuroimaging initiative subjects. Ann Neurol 2009;65(4):403-13
    • (2009) Ann Neurol , vol.65 , Issue.4 , pp. 403-13
    • Shaw, L.M.1    Vanderstichele, H.2    Knapik-Czajka, M.3
  • 95
    • 77949425172 scopus 로고    scopus 로고
    • Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimers disease
    • Fagan AM, Mintun MA, Shah AR, et al. Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimers disease. EMBO Mol Med 2009;1(8-9):371-80
    • (2009) EMBO Mol Med , vol.1 , Issue.8-9 , pp. 371-80
    • Fagan, A.M.1    Mintun, M.A.2    Shah, A.R.3
  • 96
    • 70350152831 scopus 로고    scopus 로고
    • Relationships between biomarkers in aging and dementia
    • Jagust WJ, Landau SM, Shaw LM, et al. Relationships between biomarkers in aging and dementia. Neurology 2009;73(15):1193-9
    • (2009) Neurology , vol.73 , Issue.15 , pp. 1193-9
    • Jagust, W.J.1    Landau, S.M.2    Shaw, L.M.3
  • 97
    • 69449085355 scopus 로고    scopus 로고
    • Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding
    • Tolboom N, van der Flier WM, Yaqub M, et al. Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding. J Nucl Med 2009;50(9):1464-70
    • (2009) J Nucl Med , vol.50 , Issue.9 , pp. 1464-70
    • Tolboom, N.1    Van Der Flier, W.M.2    Yaqub, M.3
  • 98
    • 67349227896 scopus 로고    scopus 로고
    • Beta amyloid in Alzheimers disease: Increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid
    • Grimmer T, Riemenschneider M, Forstl H, et al. Beta amyloid in Alzheimers disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiatry 2009;65(11):927-34
    • (2009) Biol Psychiatry , vol.65 , Issue.11 , pp. 927-34
    • Grimmer, T.1    Riemenschneider, M.2    Forstl, H.3
  • 100
    • 79952740168 scopus 로고    scopus 로고
    • Transforming cerebrospinal fluid Abeta42 measures into calculated Pittsburgh compound B units of brain A [beta] amyloid
    • Weigand SD, Vemuri P, Wiste HJ, et al. Transforming cerebrospinal fluid Abeta42 measures into calculated Pittsburgh compound B units of brain A [beta] amyloid. Alzheimers Dement 2011;7(2):133-41
    • (2011) Alzheimers Dement , vol.7 , Issue.2 , pp. 133-41
    • Weigand, S.D.1    Vemuri, P.2    Wiste, H.J.3
  • 101
    • 73549123897 scopus 로고    scopus 로고
    • Absence of Pittsburgh compound B detection of cerebral amyloid-beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: A case report
    • Cairns NJ, Ikonomovic MD, Benzinger T, et al. Absence of Pittsburgh compound B detection of cerebral amyloid-beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. Arch Neurol 2009;66(12):1557-62
    • (2009) Arch Neurol , vol.66 , Issue.12 , pp. 1557-62
    • Cairns, N.J.1    Ikonomovic, M.D.2    Benzinger, T.3
  • 103
    • 34248190279 scopus 로고    scopus 로고
    • A-beta oligomers: A decade of discovery
    • Walsh DM, Selkoe DJ. A-beta oligomers: a decade of discovery. J Neurochem 2007;101(5):1172-84
    • (2007) J Neurochem , vol.101 , Issue.5 , pp. 1172-84
    • Walsh, D.M.1    Selkoe, D.J.2
  • 104
    • 77958522371 scopus 로고    scopus 로고
    • Hippocampal CA1 apical neuropil atrophy in mild Alzheimer disease visualized with 7-T MRI
    • Kerchner GA, Hess CP, Hammond-Rosenbluth KE, et al. Hippocampal CA1 apical neuropil atrophy in mild Alzheimer disease visualized with 7-T MRI. Neurology 2010;75(15):1381-7
    • (2010) Neurology , vol.75 , Issue.15 , pp. 1381-7
    • Kerchner, G.A.1    Hess, C.P.2    Hammond-Rosenbluth, K.E.3
  • 105
    • 79953651513 scopus 로고    scopus 로고
    • 18F-THK523: A novel in vivo tau imaging ligand for Alzheimers disease
    • Fodero-Tavoletti MT, Okamura N, Furumoto S, et al. 18F-THK523: a novel in vivo tau imaging ligand for Alzheimers disease. Brain 2011;134(4):1089-100
    • (2011) Brain , vol.134 , Issue.4 , pp. 1089-100
    • Fodero-Tavoletti, M.T.1    Okamura, N.2    Furumoto, S.3
  • 106
    • 80054891673 scopus 로고    scopus 로고
    • Discovery of Novel [18F]-PET Agents for Imaging Neurofibrillary Tangles (NFTs)
    • Paris France
    • Kolb H. Discovery of Novel [18F]-PET Agents for Imaging Neurofibrillary Tangles (NFTs). Alzheimers Association International Conference. Paris, France, 2011
    • (2011) Alzheimers Association International Conference
    • Kolb, H.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.